SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T.

Hartrampf, Philipp E; Hüttmann, Thomas; Seitz, Anna Katharina; Kübler, Hubert; Serfling, Sebastian E; Schlötelburg, Wiebke; Michalski, Kerstin; Rowe, Steven P; Pomper, Martin G; Buck, Andreas K; Eberlein, Uta; Werner, Rudolf A

SUV_mean on baseline [¹⁸F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [¹⁷⁷Lu]Lu-PSMA I&T.

Hartrampf, Philipp E; Hüttmann, Thomas; Seitz, Anna Katharina; Kübler, Hubert; Serfling, Sebastian E; Schlötelburg, Wiebke; Michalski, Kerstin; Rowe, Steven P; Pomper, Martin G; Buck, Andreas K; Eberlein, Uta; Werner, Rudolf A.

Afiliação

Hartrampf PE; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. Hartrampf_P@ukw.de.
Hüttmann T; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Seitz AK; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Kübler H; Department of Urology and Paediatric Urology, University Hospital Würzburg, Würzburg, Germany.
Serfling SE; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Schlötelburg W; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Michalski K; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Rowe SP; The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Pomper MG; The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Buck AK; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Eberlein U; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
Werner RA; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.

Eur J Nucl Med Mol Imaging ; 50(11): 3465-3474, 2023 09.

Article em En | MEDLINE | ID: mdl-37272956

Assuntos

Antígeno Prostático Específico; Neoplasias de Próstata Resistentes à Castração; Masculino; Humanos; Resultado do Tratamento; Estudos Retrospectivos; Antígeno Prostático Específico/uso terapêutico; Neoplasias de Próstata Resistentes à Castração/diagnóstico por imagem; Neoplasias de Próstata Resistentes à Castração/radioterapia; Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico; Dipeptídeos/uso terapêutico; Tomografia por Emissão de Pósitrons; Compostos Heterocíclicos com 1 Anel/uso terapêutico; Lutécio/uso terapêutico

Palavras-chave

Overall survival; PSMA; Prostate cancer; Radioligand therapy; Theranostics; [177Lu]Lu-PSMA I&T; [18F]PSMA-1007

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antígeno Prostático Específico / Neoplasias de Próstata Resistentes à Castração Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google